Curcumin for Type 2 Diabetic Patients

Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01052597

Enrollment

200

Registered

2010-01-20

Start date

2009-07-31

Completion date

2010-03-31

Last updated

2010-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Abnormalities, Type 2 Diabetes Mellitus

Keywords

Type 2 diabetes, Metabolic syndrome, cardiovascular risk

Brief summary

There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.

Interventions

DRUGcurcumin

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

35 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetic patients aged 35 years or older and did not use insulin during the first 5 years of treatment after being diagnosed (with or without symptoms listed in the following inclusion criteria) * Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl) * Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs) * Obesity (BMI ≥ 25)

Exclusion criteria

* Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the inclusion criteria item 1-4) * Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease * Current diagnosis of end stage renal function with serum creatinine \> 2.0 mg/dl or on renal dialysis * Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range

Design outcomes

Primary

Measure	Time frame
to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients	12 months

Secondary

Measure	Time frame
To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance	12 months

Countries

Thailand

Contacts

Primary ContactSomlak Chuengsamarn, Medical Doctor

somlukc@swu.ac.th+6637-39-5085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026